IGF-1 IGF-2 Chimeric Polypeptides Evading Serum Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin-like growth factor (IGF) therapies, such as IGF1 and IGF2, have limitations in therapeutic activity and stability, particularly in evading serum binding proteins and achieving targeted delivery to specific tissues like muscle cells, which restricts their effectiveness in treating conditions like muscle atrophy and growth deficiencies.
Innovation Solution
Development of IGF2-IGF1 and IGF1-IGF2 chimeric polypeptides comprising specific amino acid sequences and fusion components like multimerizing, targeting ligands, and immunoglobulin domains to enhance biological activity, stability, and tissue penetrability, allowing evasion of serum binding proteins and targeted delivery to muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural IGF1 or IGF2 molecules are used for therapy, then they can treat growth deficiencies and tissue wasting, but they have limited therapeutic activity and are easily sequestered by serum binding proteins
Solution Approach 1:
The patent creates chimeric polypeptides that combine portions of IGF1 and IGF2 into a single hybrid molecule. This composite structure allows the chimera to evade serum binding proteins while maintaining therapeutic activity, effectively combining the beneficial properties of both parent molecules to overcome the limitations of using either molecule alone.
Solution Approach 2:
The chimeric polypeptides are designed with specific amino acid sequences from IGF1 and IGF2 in particular regions, allowing different parts of the molecule to have specialized functions. The fusion component is strategically positioned to provide evasion of serum binding proteins while the IGF-derived components maintain receptor binding activity.
2Reliability
If IGF therapies are administered to achieve targeted delivery to muscle cells, then they can improve muscle-related conditions, but they lack sufficient tissue penetrability and stability
Solution Approach 1:
The chimeric polypeptides combine structural elements from both IGF1 and IGF2, creating a more stable molecule that resists degradation while maintaining the ability to penetrate target tissues. The fusion component adds stability without compromising the tissue penetrability provided by the IGF-derived portions.
3Reliability
If fusion components are added to enhance functionality, then the chimeric polypeptide can evade serum binding proteins and improve stability, but the molecular complexity increases
Solution Approach 1:
The patent merges multiple functions into a single chimeric polypeptide molecule. The IGF1 and IGF2 portions are fused together with a connecting sequence, combining receptor binding activity, serum binding protein evasion, and enhanced stability into one integrated molecular structure, reducing the need for separate therapeutic agents.
Data Source
AI summary
Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.